Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers [Yahoo! Finance]
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: Yahoo! Finance
Tevogen Bio plans to continue using its ExacTcell TM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma. WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings (Tevogen) ( Nasdaq TVGN ), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. Neal Flomenberg, MD, Tevogen's Chief Scientific Officer, explains the company's oncology pipeline strategy. “CTLs can be used for cancer treatments in several ways. Certain cancers are virally driven and can be targeted very similarly to targeting other viral infections. Our overwhelmingly positive experience with TVGN 489 gives us confidence that such an approach would succeed. For example, virtually all cases of cervical cancer are caused by Human Papilloma Virus (HPV). After being infected by HPV, the virus remains in the cells before
Show less
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives [Yahoo! Finance]Yahoo! Finance
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational ObjectivesGlobeNewswire
- Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives [Yahoo! Finance]Yahoo! Finance
- Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational ObjectivesGlobeNewswire
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments [Yahoo! Finance]Yahoo! Finance
TVGN
Sec Filings
- 5/2/24 - Form 8-K
- 4/29/24 - Form 8-K/A
- 4/29/24 - Form 10-K
- TVGN's page on the SEC website